5-[3-Bromo-4-(dimethylamino)phenyl]-2,3,5,6-tetrahydro-2,2-dimethylbenzo[a]phenanthridin-4(1H)-one
CAS : 311795-38-7
Ref. 3D-LMA79538
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté |
Informations sur le produit
5-[3-Bromo-4-(dimethylamino)phenyl]-2,3,5,6-tetrahydro-2,2-dimethylbenzo[a]phenanthridin-4(1H)-one (TZT) is an experimental drug that inhibits glutaminase and is used to treat cancer. It has been shown to inhibit the growth of human epidermal growth factor receptor 2 (HER2), mda-mb231 breast cancer cells and human CD4+ lymphocytes. TZT also inhibits the production of glutamine in cancer cells. This inhibition leads to a decrease in the synthesis of proteins and DNA, which may lead to apoptosis or cell death. TZT has been shown to be effective against a number of carcinoma cell lines including cervical cancer and is not toxic for normal cells such as fetal bovine serum or healthy skin fibroblasts.